



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The COVID-19 Vaccine and Current Debate on Vaccination Policies

Can Türk , Şükrü Volkan Özgüven 

Dear Editor,

We read with interest the Letter to the Editor entitled “COVID-19 vaccine prioritization must be driven by science” by Yale et al., published recently in the Erciyes Medical Journal (1). It is well known that the new human viral pathogen, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is the etiologic agent of coronavirus disease 2019 (COVID-19). After the emergence of COVID-19 in December 2019 in Wuhan, China and its subsequent rapid spread around the world, vaccine development studies were initiated in many countries (2). In less than a year, intense scientific work has resulted in the development of numerous vaccines with different mechanisms of action. However, the speed and process of vaccine development and administration have raised concerns regarding their efficacy and safety.

To allay these concerns, two different points need to be considered: First, one of the most important reasons for such rapid vaccine development was the world’s preparedness for an infectious respiratory viral pathogen in terms of science and laboratory infrastructure. Second, the experience gained from the MERS and SARS-CoV epidemics contributed greatly in the fight against COVID-19 (2).

Scientific data released by the Centers for Diseases Control and Prevention indicate that COVID-19 morbidity and mortality may increase in the future (3). All vaccines in use have successfully completed preclinical and clinical testing (3, 4). Considering these factors, as well as the disease’s rapid spread, we advise vaccination of all individuals regardless of age. Implementation of infection control measures and vaccination are essential for global prevention considering the lack of effective antiviral agents.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – CT, ŞVÖ; Design – CT, ŞVÖ; Supervision – CT, ŞVÖ; Resource – CT, ŞVÖ; Materials – CT, ŞVÖ; Data Collection and/or Processing – CT, ŞVÖ; Analysis and/or Interpretation – CT, ŞVÖ; Literature Search – CT, ŞVÖ; Writing – CT, ŞVÖ; Critical Reviews – CT, ŞVÖ.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Yale S, Tekiner H, Mazza JJ, Yale ES. COVID-19 vaccine prioritization must be driven by science. Erciyes Med J 2021; 43(3): 305–6. [\[CrossRef\]](#)
2. Sharma O, Sultan AA, Ding H, Trigg CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol 2020; 11: 585354. [\[CrossRef\]](#)
3. Liu Q, Xu K, Wang X, Wang W. From SARS to COVID-19: What lessons have we learned? J Infect Public Health 2020; 13(11): 1611–8. [\[CrossRef\]](#)
4. Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, et al. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. JAMA Intern Med 2020; 180(10): 1336–44.

Cite this article as:
Türk C, Özgüven ŞV.
The COVID-19 Vaccine
and Current Debate on
Vaccination Policies.
Erciyes Med J
2021; 43(3): 307.

Department of Medical
Microbiology, Lokman
Hekim University Faculty of
Medicine, Ankara, Turkey

Submitted
30.12.2020

Accepted
04.01.2021

Available Online
15.02.2021

Correspondence
Can Türk,
Department of Medical
Microbiology, Lokman
Hekim University Faculty of
Medicine, Ankara, Turkey
Phone: +90 542 457 18 55
e-mail:
can.turk@lokmanhekim.edu.tr

©Copyright 2021 by Erciyes
University Faculty of Medicine -
Available online at
www.erciyesmedj.com